Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:EXOZNASDAQ:FGENNASDAQ:LRMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$1.83-2.1%$1.39$0.91▼$6.22$153.20M2.152.57 million shs1.55 million shsEXOZExozymes$13.90-0.7%$12.06$8.50▼$23.99$116.32MN/A18,530 shs2,963 shsFGENFibroGen$0.32+0.0%$0.31$0.18▼$1.53$32.14M0.862.05 million shs586,914 shsLRMRLarimar Therapeutics$2.30+15.6%$2.10$1.61▼$11.20$147.26M0.93779,582 shs2.34 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine-2.14%+12.96%+18.06%-4.69%-64.12%EXOZExozymes-0.71%-4.79%+26.36%-17.75%+1,389,999,900.00%FGENFibroGen+0.03%-3.17%-2.87%-22.11%-72.81%LRMRLarimar Therapeutics+15.58%+19.17%-3.77%-24.09%-67.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.3933 of 5 stars3.14.00.04.23.21.71.3EXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AFGENFibroGen4.0951 of 5 stars3.32.00.04.71.93.30.6LRMRLarimar Therapeutics1.8772 of 5 stars3.61.00.00.03.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.29Hold$5.36193.09% UpsideEXOZExozymes 0.00N/AN/AN/AFGENFibroGen 2.50Moderate Buy$10.003,043.67% UpsideLRMRLarimar Therapeutics 3.10Buy$20.43788.20% UpsideCurrent Analyst Ratings BreakdownLatest FGEN, EDIT, EXOZ, and LRMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.005/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.004/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/25/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00 ➝ $26.003/25/2025LRMRLarimar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/25/2025LRMRLarimar TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.003/18/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$35.84M4.27N/AN/A$4.27 per share0.43EXOZExozymesN/AN/AN/AN/AN/AN/AFGENFibroGen$7.00M4.59N/AN/A($1.87) per share-0.17LRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)EXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AFGENFibroGen-$284.23M-$0.10N/AN/AN/A-67.66%N/A-36.17%8/5/2025 (Estimated)LRMRLarimar Therapeutics-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%8/6/2025 (Estimated)Latest FGEN, EDIT, EXOZ, and LRMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A5/12/2025Q1 2025FGENFibroGen$0.03-$0.16-$0.19$0.05$2.00 million$2.70 million4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/A3/17/2025Q4 2024FGENFibroGen-$0.08-$0.08N/A$0.18$24.91 million$3.14 million3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.753.75EXOZExozymesN/AN/AN/AFGENFibroGenN/A1.281.16LRMRLarimar TherapeuticsN/A13.1013.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%EXOZExozymesN/AFGENFibroGen72.71%LRMRLarimar Therapeutics91.92%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%EXOZExozymesN/AFGENFibroGen1.98%LRMRLarimar Therapeutics4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableEXOZExozymes298.37 millionN/AN/AFGENFibroGen570101.04 million98.78 millionOptionableLRMRLarimar Therapeutics3064.03 million61.57 millionOptionableFGEN, EDIT, EXOZ, and LRMR HeadlinesRecent News About These CompaniesWoodline Partners LP Sells 621,869 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)May 27 at 4:32 AM | marketbeat.comLarimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stockMay 24, 2025 | investing.comLarimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside PotentialMay 21, 2025 | insidermonkey.comJanus Henderson Group PLC Increases Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR)May 18, 2025 | marketbeat.comCubist Systematic Strategies LLC Boosts Stock Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR)May 17, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from AnalystsMay 13, 2025 | marketbeat.comDAFNA Capital Management LLC Cuts Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR)May 10, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Purchased by Alyeska Investment Group L.P.May 8, 2025 | marketbeat.comWhy Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 6.40%May 6, 2025 | aaii.comLeerink Partnrs Issues Positive Estimate for LRMR EarningsMay 6, 2025 | marketbeat.comQ2 EPS Estimate for Larimar Therapeutics Reduced by AnalystMay 6, 2025 | marketbeat.comWilliam Blair Issues Positive Outlook for LRMR EarningsMay 6, 2025 | marketbeat.comLarimar Therapeutics Advances Nomlabofusp Amid Financial LossMay 5, 2025 | tipranks.comBrokers Set Expectations for LRMR Q2 EarningsMay 4, 2025 | marketbeat.comLarimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp DevelopmentMay 4, 2025 | msn.comLarimar Therapeutics (LRMR) Projected to Post Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Acquired by Adage Capital Partners GP L.L.C.May 1, 2025 | marketbeat.comLarimar Therapeutics Reports First Quarter 2025 Financial ResultsApril 30, 2025 | globenewswire.comLarimar Therapeutics: Initiating Hold Rating With Upcoming CatalystsApril 5, 2025 | seekingalpha.comLarimar Therapeutics Advances Nomlabofusp Program Amid Regulatory SupportMarch 27, 2025 | msn.comLarimar Therapeutics price target raised to $16 from $15 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookAlphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden DriverArcher Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue LaunchBy Jeffrey Neal Johnson | May 14, 2025View Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue LaunchCRSPR Stock Could Be Ready to Deliver on Its Massive PromiseBy Chris Markoch | May 16, 2025View CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseFGEN, EDIT, EXOZ, and LRMR Company DescriptionsEditas Medicine NASDAQ:EDIT$1.83 -0.04 (-2.14%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.84 +0.00 (+0.27%) As of 05/29/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Exozymes NASDAQ:EXOZ$13.90 -0.10 (-0.71%) As of 05/29/2025 02:44 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.FibroGen NASDAQ:FGEN$0.32 +0.00 (+0.03%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.32 +0.00 (+0.60%) As of 05/29/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Larimar Therapeutics NASDAQ:LRMR$2.30 +0.31 (+15.58%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$2.32 +0.02 (+0.87%) As of 05/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
